$TGT Cashflow Statement | Understand Stock

$TGT

$148.53 +$0.00 (0.0%) After hours

$TGT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Jan 31, 2026	FY2024 12 months to Feb 1, 2025	FY2023 12 months to Feb 3, 2024	FY2022 12 months to Jan 28, 2023	FY2021 12 months to Jan 29, 2022
Operating activities
Earnings from discontinued operations, net of tax
Net earnings from continuing operations
Net earnings
Adjustments to reconcile net earnings to cash provided by operations:
Depreciation and amortization
Share-based compensation expense
Deferred income taxes
Gain on Dermstore sale
Loss on debt extinguishment
Noncash (gains) / losses and other, net
Changes in operating accounts:
Inventory
Other assets
Accounts payable
Accrued and other liabilities

Cash provided by operating activities—continuing operations
Cash provided by operating activities—discontinued operations
Accrued and other liabilities
Cash provided by operating activities

Investing activities
Expenditures for property and equipment
Proceeds from disposal of property and equipment
Proceeds from Dermstore sale
Other
Cash used in investing activities
Financing activities
Additions to long-term debt
Reductions of long-term debt
Dividends paid
Repurchase of stock
Shares withheld for taxes on share-based compensation
Stock option exercises
Cash used in financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental information
Interest paid, net of capitalized interest
Income taxes paid
Leased assets obtained in exchange for new finance lease liabilities
Leased assets obtained in exchange for new operating lease liabilities

Comments